Immunwork
Taipei, Taiwan· Est.
Taiwan biotech creating ultra‑long‑acting endocrine drugs and antibody‑based oncology candidates.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech creating ultra‑long‑acting endocrine drugs and antibody‑based oncology candidates.
EndocrinologyOncology
Technology Platform
Fatty‑acid‑bundle chemistry enables ultra‑long‑acting drug conjugates; ADC/ARC platforms deliver cytotoxic or radiotherapeutic payloads via antibody targeting.
Opportunities
Ultra‑long‑acting endocrine therapeutics can capture premium market share by improving adherence; ADC/ARC platforms open pathways to high‑value oncology collaborations.
Risk Factors
Clinical efficacy and safety must be proven in larger trials; regulatory approval for novel conjugate chemistries may be uncertain; competition from established long‑acting injectables.
Competitive Landscape
Differentiates through fatty‑acid‑based half‑life extension and novel antibody conjugation chemistries, competing against companies like Novo Nordisk, Eli Lilly, and Seagen.